Optical coherence tomography guidance beneficial for managing coronary bifurcation lesions
Bookmark1. In this randomized controlled trial, percutaneous coronary intervention (PCI) performed...
Read MoreNov 15, 2023
Bookmark1. In this randomized controlled trial, percutaneous coronary intervention (PCI) performed...
Read MoreNov 15, 2023
Bookmark1. Efficacy of spesolimab appeared to be dose-dependent with high-dose spesolimab leading...
Read MoreNov 14, 2023
Bookmark1. A greater percentage of patients who received concurrent stereotactic radiation therapy...
Read MoreNov 14, 2023
Bookmark1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3...
Read MoreNov 14, 2023
Bookmark1. In this randomized controlled trial, in patients with treatment-resistant depression...
Read MoreNov 14, 2023
Bookmark1. In this randomized controlled trial, tight versus liberal blood glucose control...
Read MoreNov 11, 2023
Bookmark1. In this randomized controlled trial, in patients with heart failure with preserved...
Read MoreNov 10, 2023
Bookmark1. In this randomized controlled trial, over a period of 240 weeks, solanezumab did not...
Read MoreNov 9, 2023
Bookmark1. Total knee arthroplasty was found to decrease the incidence of depression among...
Read MoreNov 9, 2023
Bookmark1. Median overall survival increased by 3.2 months in the sacituzumab govitecan group...
Read MoreNov 8, 2023
Bookmark1. In this cross-sectional study, spiritual intelligence was a significant predictor of...
Read MoreNov 8, 2023
Bookmark1. Avacincaptad pegol significantly slowed geographic atrophy over 12 months. 2. Exudative...
Read MoreNov 8, 2023
Bookmark1. This cross-sectional study found that physical activity, employment, pain, and sense of...
Read MoreNov 7, 2023
Bookmark1. The progression-free survival was 24.8 months in the selpercatinib group vs 11.2 months in the control group (chemotherapy ± pembrolizumab), with an HR of 0.46. 2. Grade ≥3 adverse events occurred in 70% vs 57%...
Read MoreNov 1, 2023
Bookmark1. 30-day mortality was comparable among patients on VA-ECMO and medical therapy alone. 2....
Read MoreOct 31, 2023
Bookmark1. This randomized controlled trial found that children with obstructive sleep apnea...
Read MoreOct 31, 2023
Bookmark1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group...
Read MoreOct 31, 2023
Bookmark1. Median overall survival and progression-free survival were greater in the tebentafusp...
Read MoreOct 26, 2023
Bookmark1. This analysis of a population-based cohort found that those who engaged in high and...
Read MoreOct 25, 2023
Bookmark1. In surveyed sample, parental hesitancy towards routine vaccination during the pandemic...
Read More